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Introduction
============

Thrombotic microangiopathy (TMA) is classified into three major categories including, Shiga toxin-producing *Escherichia coli* hemolytic uremic syndrome (STEC-HUS), thrombotic thrombocytopenic purpura, and atypical hemolytic uremic syndrome (aHUS) \[[@REF1]\]. The majority of HUS cases are sporadic and triggered by infection, most notably certain strains of *E. coli* and other bacteria that produce toxic substances called Shiga-like toxins (SLTs). HUS most often affects children younger than 10 years and is not known to be associated with genetic mutations \[[@REF1]\]. However, aHUS is usually due to a genetic or acquired defect in the regulation of complement activation on host cells \[[@REF2]\]. The clinical presentation of aHUS and STEC‐HUS is similar. aHUS earned its name because it is not caused by either of the common etiological factors for typical HUS (Shiga toxin-produced by*E. coli* O157:H7 or *Shigella dysenteriae*) \[[@REF3],[@REF4]\]. aHUS accounts for 5-10% of all documented cases of HUS and is associated with a poor prognosis \[[@REF5]\]. It is a rare disease with an estimated incidence of 1 in 500,000 people per year in the United States. Triggers for the development of aHUS are more diverse and include drugs, complement regulation deficits, infections, and pregnancy \[[@REF6]\]. In the literature, *Clostridium difficile* infection is described as a rare precipitant of aHUS \[[@REF7]-[@REF9]\].

Case presentation
=================

A 60-year-old female with a medical history of hypertension, which was well-controlled with lisinopril, presented to the emergency department with the complaint of multiple episodes of vomiting, profuse watery diarrhea, and decrease urine output for the last four days. One month before the admission, she had received ciprofloxacin for urinary tract infection. She appeared acutely ill with a blood pressure of 139/88 mmHg, a pulse of 100 beats/minute, a respiratory rate of 23 breaths/minute, and a temperature of 98°F. On physical examination, she had dry mucus membranes and yellow sclera. The abdomen was slightly distended with generalized tenderness but without guarding and rebound. The rest of the physical examination was unremarkable.

The blood work revealed the following: creatinine of 11.6 mg/dL (baseline creatinine was 1.3 mg/dL eight months ago), hemoglobin of 10.5 g/dL, hematocrit of 33%, reticulocytosis of 4.5 %, white cell count of 18.0 x 10^9^/L, and platelet count of 107 x 10^9^/L. The patient had an LDH (lactate dehydrogenase) level of 3,441 U/L and unconjugated bilirubin of 3.7 mg/dL. Peripheral blood smear showed a moderate number of schistocytes. Liver function tests and coagulation profile were within the normal range. Urine complete examination was positive for dysmorphic red blood cells and protein. Stool on the first day of admission was positive for C*. difficile* toxin A by enzyme immunoassay (EIA). Stool assay for SLT by EIA returned negative, and stool cultures were negative for *E. Coli* O157:H7 and other enteric pathogens. Antineutrophil cytoplasmic antibodies (ANCA), antinuclear antibodies (ANA), and double-stranded deoxyribonucleic acid (dsDNA) were negative. Serum folic acid and vitamin B12 levels were normal. Test results for hepatitis B surface antigen, hepatitis C antibody, human immunodeficiency virus (HIV), and coombs test were negative. Complement components were low, with C3 of 0.73 g/L (reference range \[RR\]: 0.85-1.60) and C4 of 0.08 g/L (RR: 0.12-0.36). The results are summarized in Table [1](#TAB1){ref-type="table"}.

###### Test results at presentation

LDH, lactate dehydrogenase; BUN, blood urea nitrogen; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALP, alkaline phosphatase; PT, prothrombin time; APTT, activated partial thromboplastin time; INR, internal normalized ratio; C3 complement component 3; C4, complement component 4

  ------------------------ ---------------- -------------------
  Tests                    Result           Reference Range
  Hemoglobin               10.5 g/dL        12-15 g/dL
  Hematocrit               33%               40-52%
  Reticulocytes            4.5 %            0.5-1.5%
  White cell count         18.0 x 10^9^/L   4-10 x 10^9^/L
  Platelet count           107 x 10^9^/L    150-400 x 10^9^/L
  LDH                      3441 U/L         50-150 U/L
  Unconjugated bilirubin   3.7 mg/dL        0.2-1.1 mg/dL
  Creatinine               11.6 mg/dL       0.8-1.3 mg/dL
  BUN                      37 mg/dL          8-21 mg/dL
  ALT                      31 IU/L          5-42 IU/L
  AST                      37 IU/L          5-40 IU/L
  ALP                      89 IU/L          50-150 IU/L
  PT                       12 seconds       11-14 seconds
  APTT                     18 seconds       20-40 seconds
  INR                      1.1               0.9-1.2
  C3                       0.73 g/L          0.85-1.60 g/L
  C4                       0.08 g/L         0.12-0.36 g/L
  ------------------------ ---------------- -------------------

Renal ultrasound revealed normal-sized kidneys with grade one echogenicity. Liver ultrasound was normal without biliary tract obstruction. Intravenous metronidazole and oral vancomycin started for *C. difficile*. Nephrology and hematology consultation was sought, and the multidisciplinary team decided to start plasmapheresis for a probable aHUS. ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13) activity levels were noted before the initiation of plasmapheresis. ADAMTS13 activity was 71%, which is within the normal reference range. We did not perform genetic studies due to limited resources.

We made a diagnosis of aHUS in the absence of STEC infection with regular ADAMTS13 activity. The patient underwent plasmapheresis and hemodialysis for seven days in the intensive care unit. During the hospital stay, her creatinine peaked at 14.4md/dL, and the nadir of her platelet count was 61,000/mm^3^. She received eculizumab infusion on the 9th day of hospital admission. She gradually improved, and at the time of discharge her LDH was 400 U/L and the creatinine level was 4.4 mg/dL. The graph of the time course of the patient\'s creatinine level and LDH is shown in Figure [1](#FIG1){ref-type="fig"}.
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She was prescribed eculizumab upon discharge according to standard protocol. She followed up in the outpatient clinic after four weeks. Eculizumab treatment led to normalization in hemoglobin, platelet count, LDH, and creatinine levels.

Discussion
==========

TMA presents with thrombocytopenia, nonimmune microangiopathic hemolytic anemia, and end-organ damage \[[@REF5]\]. Small vessel occlusion leads to hypoxia and ischemic end-organ damage, and the endothelial injury leads to platelet activation that causes platelet aggregation and thrombus formation. Acute kidney injury is the most common presentation due to the propensity of glomerular circulation to endothelial damage and occlusion \[[@REF10],[@REF11]\]. HUS is a form of TMA defined as a triad of intravascular hemolysis, thrombocytopenia, and acute renal failure \[[@REF12]\]. HUS is labeled as typical when caused by Shiga toxin produced by *E. coli* O157:H7 or S. dysenteriae and is labeled atypical when caused by mutations or autoantibodies activating complement system \[[@REF12]\]. Around 10% of HUS cases in children and the majority of the adult cases fall in the category of aHUS. Complement gene pathway mutations are recognized in only 50-60% of cases of aHUS, whereas the rest of the cases have impaired diacylglycerol kinase ε (DGKε) activity, cobalamin C deficiency, or plasminogen deficiency. *Clostridium difficile* infection is a rare precipitant of aHUS. Our patient was positive for *C. difficile* toxin A by EIA. Test for SLT by EIA was negative. Several treatment options are described in cases of *C. difficile*-associated aHUS, including steroids, antibiotics, and plasma exchange with favorable results \[[@REF7]\]. Terminal complement inhibitors have emerged as an effective therapy for aHUS \[[@REF13]\]. Eculizumab controls hemolysis and improves renal function \[[@REF14]\]. Renal transplant in patients with aHUS is not recommended due to graft failure and high recurrence rate \[[@REF15]\]. Patients with no previous history of aHUS also develop de novo aHUS after renal transplant \[[@REF15]\]. Around 50% of patients with aHUS progress to end-stage renal disease \[[@REF16]\]. Our patient responded positively with normalization of hemoglobin, platelet count, LDH, and creatinine levels. The use of eculizumab leads to the resolution of symptoms in patients with *C. difficile*-associated aHUS \[[@REF9]\].

Conclusions
===========

aHUS carries a poor prognosis, and the mortality rate is high because most of the patients are diagnosed late in the disease course. *Clostridium difficile* is a rare precipitant of aHUS. Depending on the stage of the disease, treatment options include plasma exchange, eculizumab, and/or dialysis. Plasma exchange therapy is the most common intervention. Most of the patients require renal replacement therapy in the form of dialysis or renal transplant. Eculizumab is an effective therapy for the resolution of hemolysis and normalizing renal function.
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